Business Wire

RHYTHMONE

11.9.2019 07:32:09 CEST | Business Wire | Press release

Share
RhythmOne Launches its Programmatic Platform in Asia-Pacific and Latin America

RhythmOne , LLC, a Tremor International company, today announces it will be bringing the infrastructure, scale and success of its programmatic platform to the Asia-Pacific (APAC) and Latin American (LATAM) markets. The announcement will also be made at the international digital marketing conference DMEXCO, following the company’s successful expansion into Europe earlier this year.

To lead international expansion efforts, today the company also announces the appointment of industry veterans Assaf Suprasky as General Manager of Tremor International’s Israel operations and Gal Topaz as Senior Vice President, Exchange Operations and Business Development. Both executives come to RhythmOne with deep experience in advanced mobile and digital video advertising solutions. Prior to his role at RhythmOne, Suprasky was CEO at personalized advertising specialist myThings, and Topaz was the CEO of programmatic group Feature Forward. Physical business development and sales teams are also now in place and active in Europe, APAC, and LATAM.

The RhythmOne Programmatic Platform is among the world’s largest brand-safe programmatic platforms. Offering technological efficiency at virtually every stage of the process, the global platform helps to effectively connect buyers to sellers and engage consumers on formats spanning video, connected TV (CTV), in-app, and display. A proven leader in the US, the RhythmOne Programmatic Platform reaches 358.8 million uniques globally* and is directly integrated with 600+ premium publishers – resulting in over 10,000 properties. The April 2019 acquisition of RhythmOne by Tremor International (AIM: TRMR) has laid the groundwork for further expansion initiatives and enhancements to the platform, including leveraging the large geographical footprint of the group’s performance division by expanding the RhythmOne Programmatic Platform into Asia.

With brand safety at the heart of its offering – supported by RhythmGuard, RhythmOne’s proprietary brand safety technology – and consistent top-tier ratings in Pixalate’s Seller Trust Indexes for programmatic display, mobile, and video advertising both internationally and in the US, the RhythmOne Programmatic Platform helps deliver high-quality solutions with large scale, and is integrated with the major international players including Google Exchange Bidding and Amazon A9. For publishers, RhythmOne offers a fully-integrated supply monetization platform (SSP) to maximize the value of inventory across desktop, mobile, and connected TV devices. Powered by an enhanced technology stack, the RhythmOne SSP provides web publishers and app developers with full access to a global programmatic ad marketplace.

“We are proud to be hosting a large-scale presence at DMEXCO this year as we take our US success and bring it to the international stage in the Asia-Pacific and Latin American markets,” said Ofer Druker, CEO Tremor International. “Our platform has massive global reach, has unique features and partnerships, and, alongside our market-specific business development professionals, we provide the perfect combination of a world-class product with local support, giving us confidence in delivering our product on an international scale. We are also pleased to welcome Assaf Suprasky and Gal Topaz to the RhythmOne team and are confident that their expertise will help bolster our success by delivering results to both demand clients and supply partners on the global stage.”

*Quantcast Measure, August 2019 / 30 Day Total

-ENDS-

Notes to the editors

RhythmOne is top-rated in the most current Pixalate programmatic seller trust rankings (Q4 2018):

  • #1 US and #4 International, Global Seller Trust Index
  • #1 Mobile Seller Trust Index
  • #1 US and #2 International, Video Seller Trust Index

Since 2018, RhythmOne has been partnered with AU-based Allegiant Media as a reseller for RhythmOne in Australia and New Zealand. RhythmOne will be continuing its partnership with them.

About Tremor International

Tremor International Ltd is a global leader in advertising technologies, operating in more than 70 countries. It has three core divisions: Tremor Video (brand advertising), RhythmOne (media) and Taptica (performance advertising).

RhythmOne drives real business outcomes in multiscreen advertising. Its highly-ranked programmatic platform efficiently and effectively delivers performance, quality, and actionable data to demand and supply-focused clients and partners – and its influencer marketing offering fosters action and awareness by connecting brands with influencers who create and distribute branded content to engaged consumers.

Tremor Video helps advertisers deliver impactful brand stories across all screens through the power of creative video intelligence—innovative video technology combined with advanced audience data and captivating creative. Tremor Video is one of the largest and most innovative video advertising companies in North America, with offerings in CTV, influencer marketing, and private marketplaces.

The Taptica performance business is an end-to-end mobile technology advertising platform that helps the world's top brands reach their most valuable users with the widest range of traffic sources available today. Its proprietary technology leverages big data to target quality media at scale. It works with more than 600 advertisers including Amazon, Alibaba, Bytedance, Netmarble, Stubhub and OpenTable.

Tremor International Ltd is headquartered in Israel and maintains offices throughout the US and Canada, Asia-Pacific, Europe, India, and Latin America, and is traded on the London Stock Exchange (AIM: TRMR).

Forward-Looking Statements

This press release contains forward-looking statements. In some cases, you can identify forward-looking statements by the words "may," “likely,” "will," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. All statements other than statements of historical fact are statements that could be forward-looking statements, including, but not limited to, statements about the potential and effectiveness of RhythmOne’s programmatic platform. These forward-looking statements are subject to risks and uncertainties, assumptions and other factors that could cause actual results and the timing of events to differ materially from future results that are expressed or implied in the forward-looking statements. Factors that could cause or contribute to such differences include the dynamic and rapidly evolving sector, as well as the highly competitive industry that RhythmOne operates in, which make it difficult to evaluate prospects. These and other risk factors are discussed in RhythmOne’s Annual Report for the period ended March 31, 2018. The forward-looking statements in this article are based on information available to RhythmOne as of the date hereof, and we assume no obligation to update any forward-looking statements.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O

Data4Industry-X Empowers Industrial Organizations in Meeting Digital Product Passport Requirements20.4.2026 14:17:00 CEST | Press release

Contributing to the International Manufacturing-X Council Showcase at Hannover Messe, to improve resilience, productivity and innovation in Manufacturing Hannover Messe - Data4Industry-X, the trusted industry data space solution, builds its momentum by accelerating Digital Product Passport (DPP) compliance with trusted, secure and traceable data exchange at scale, as demonstrated at Hannover Messe April 20-24, 2026 . As theDigital Product Passport becomes a regulatory reality for manufacturing organizations, the ability to exchange data in a trusted, secure and traceable environment across the entire supply chain, in compliance with data regulations such as the Data Act, has become critical. Actively contributing to the International Manufacturing-X Council showcase, driven by LNI 4.0 association involving 16 countries, Data4Industry-X, a decentralized environment, demonstrates the use case of the DPP on the battery’s State of Health, and how the battery current capacity and performanc

Ushio Industry & Entertainment Appoints Takuya Matsumoto as President & CEO and Outlines Strategic Direction for the Next Phase20.4.2026 12:32:00 CEST | Press release

Ushio Industry & Entertainment (Ushio INE GmbH) announces the appointment of Takuya Matsumoto as President and Chief Executive Officer, marking a key milestone in the evolution of the business and its integration within the Ushio Group. With more than 20 years of experience across sales, new business development, and global operations, Takuya Matsumoto brings deep industry expertise and a strong leadership track record within Ushio. Most recently, he served as General Manager of the Global Business Unit, where he played a pivotal role in advancing global growth initiatives. A Clear Vision: A strong heritage with a forward-looking vision focused on innovation, operational excellence, and customer value Under Takuya Matsumoto’s leadership, Ushio INE will continue to build on its strong legacy while advancing its mission to deliver high-performance, high-quality lighting solutions across industrial and entertainment markets worldwide. “Our mission is to continuously deliver essential ligh

Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 202620.4.2026 12:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate in a panel entitled “Clinical Risk, Regulatory Reality and the Path to Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026, at 11am-12pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable response

PPG invests in testing line for radiation-curable coatings at Marly, France20.4.2026 11:00:00 CEST | Press release

Installation helps accelerate development cycles, reduce number of customer trials PPG (NYSE: PPG) today announced the installation of an advanced testing line for radiation-curable coatings at its R&D Center of Excellence in Marly, France. The line can test multiple curing technologies, including infrared (IR), ultraviolet (LED, excimer and arc lamps), and electron beam (EB). This investment allows the company to accurately replicate customer production conditions, helping accelerate development cycles and reduce the number of customer trials. Unlike conventional thermal curing, radiation curing requires less energy because it operates at or near ambient temperature. This reduction in energy demand can significantly lower carbon emissions by 65%*, with further gains possible when powered by renewable energy sources. In addition, UV- and EB-curable systems typically use 100% solids formulations with no solvents, reducing or eliminating volatile organic compound emissions. Beyond sustai

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye